etaracizumab   

GtoPdb Ligand ID: 6596

Synonyms: etaratuzumab | hLM60 | MEDI-522
Compound class: Antibody
Comment: Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
References
1. Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K, Lozahic S, Marty M, Faivre S. (2008)
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.
Invest New Drugs, 26 (1): 35-43. [PMID:17876527]
2. Felding-Habermann B, Cheresh DA. (1993)
Vitronectin and its receptors.
Curr. Opin. Cell Biol., 5 (5): 864-8. [PMID:7694604]
3. Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S et al.. (2006)
Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.
Mol. Cancer Ther., 5 (12): 3122-9. [PMID:17172415]
4. Wu H, Gao C. (2010)
Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity.
Patent number: US7659374. Assignee: Medimmune, Llc. Priority date: 16/08/2004. Publication date: 09/02/2010.